Entecavir is a nucleoside analog which is selective to hepatitis B virus and inhibits the synthesis and replication of hepatitis B virus DNA.
Management of chronic hepatitis B.
Once-daily dosing is recommended, with or without food.
Hypersensitivity to entecavir or any component of the product.
Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue entecavir therapy. It is not recommended for administration of entecavir to patient with hiv. Need a dosage adjustment of entecavir for patients with renal disorders (creatinine clearance <50 mL/min, and on hemodialysis).
Use in Children: TKV should not be used in children <16 years.
TKV should not be used during pregnancy or lactation. There is no adequate experience in pregnant women.
In general is headache, fatigue, dizziness, and nausea.
There is a quite strong interaction between entecavir and immunosupressan like cyclosporine and tacrolimus.
Store at room temperature (below 30°C). Protect from light.
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
FC tab 0.5 mg x 3 x 10's.